Abstract Following transplantation, the kidney is exposed to many different injuries which result in inflammation, overproduction of extracellular matrix, interstitial fibrosis and progressive loss of renal function. To date, treatment options for patients with progressive graft dysfunction are very limited. The development of new therapies requires a better understanding of the pathogenesis of transplant interstitial fibrosis and specific biomarkers to identify patients with progressive transplant fibrosis and monitor response to new therapies. Here, we review our current understanding of how and why extracellular matrix accumulates and the relationship between fibrosis and inflammation. In particular, we focus on the role of heparan sulphate that regulates recruitment, migration and differentiation of interstitial cells and also acts as a reservoir for multiple cytokines and growth factors.
Introduction Clinical Summary
Renal transplantation is the best option for patients with end-stage kidney disease. In 2012, at least 77,800 kidney transplants were performed worldwide [1] . In the UK, graft survival rate after renal transplantation is 85-95 % after 1 year, 70-80 % after 5 years and 50-60 % after 15 years. Ten years after kidney transplantation, over 50 % of patients will have evidence of progressive chronic graft dysfunction [2] . In order to reduce injury and prolong organ survival, a clear understanding of the different physiological events occurring before, during and after transplantation is essential.
Risk Factors for Interstitial Fibrosis/Tubular Atrophy
Before transplantation, the integrity of the organ depends on the donor. Cadaveric transplantation, donor vascular pathology and age of the donor are important factors that impact early and long-term graft function. Transplantation involves a period of ischemia, followed by reperfusion, during which there is an oxidative burst with increased production of reactive oxygen and nitrogen species, pH changes, an increase in mitochondrial calcium and, if severe, cell death. Haemodynamic changes after transplantation are also important with glomerular hypertension and angiotensin II-mediated remodelling leading to impaired kidney function. Additionally, after transplantation, urinary infection and drug toxicity, in particular, the pro-fibrotic effects of calcineurin inhibitors are also associated with graft dysfunction.
Classification of Interstitial Fibrosis
In the past, research in renal transplant was hindered by a lack of a common classification of renal transplant pathology. The Banff classification is an international standard classification of renal transplant pathology that was introduced to overcome this problem. This classification takes into account different stages in the evolution of graft inflammation and fibrosis. Since 2007, the classification considers five categories as shown in Table 1 .
Interstitial Fibrosis/Tubular Atrophy: an Active Matrix-Cell Interaction Initiation: Chemokines and Inflammation: a Glycosaminoglycan-Dependant Phenomenon
Interstitial fibrosis tubular atrophy (IFTA) can result from chronic rejection and is frequently associated with infiltration of inflammatory cells. The interaction between these inflammatory cells and the extracellular matrix (ECM) is an important factor in the development of the inflammatory response and tissue injury. Glycosaminoglycans (GAG), also known as mucopolysaccharides, are glucosidic macromolecules composed of repeating disaccharide entities. Chondroitin sulphate, dermatan sulphate, keratan sulphate and heparin/heparan sulphate (HS) are the main GAGs found in tissue. HS is synthesised by all mammalian cells; it can be found covalently attached to various protein cores and is a major component of the ECM. HS is composed of a 10-200 disaccharide subunits with a hexuronic acid that could either be D-glucuronic acid or L-iduronic acid (IdoA) linked to a D-glucosamine (GlcN). Uronyl C-5-epimerase converts D-glucuronic acid into L-iduronic acid. The resulting IdoA can be sulphated at the 2-O position by a glucosaminyl 2-O-sulfotransferase (HS2ST). GlcN can be sulphated at the 3-O, 6-O or N positions by seven glucosaminyl 3-O-sulfotransferase (HS3STs), three glucosaminyl 6-O-sulphotransferases (HS6ST) and four glucosaminyl N-deacetylase/Nsulphotransferases, respectively (NDST). Following its synthesis, HS is associated with a protein to form HS proteoglycans (HSPG) that have multiple functions in cell physiology [4] .
At present, around 50 chemokines and 20 chemokine receptors have been discovered. Chemokines consist of three antiparallel beta strands and an alpha helical region at the C-terminus. They are classified based on the position of the first two N-terminal cysteines. They can bind to specific G-protein-coupled receptors to induce migratory responses.
Chemokine signalling promotes neuronal migration and vascular remodelling and attracts cancer cells to distant sites during metastasis. During allograft rejection, chemokine expression follows a temporal pattern and their expression varies inside the graft itself [5] . Chemokines also undergo post-translational modifications during inflammation [6] , for example nitration, which can alter their biological function including leukocyte recruitment [7] .
Chemokines can bind to GAGs on cell surfaces and within the ECM. HS protects chemokines from degradation, enhances receptor binding and therefore regulates activity of chemokines, but most importantly, HS is responsible for the [3] chemokine gradient that attracts immune cells [8••] . The chemokine-GAG interaction is required for leukocyte binding to the endothelium and transmigration across the endothelium [9] and chemotaxis to the site of tissue injury [8••] as illustrated in Fig. 1 . This review will focus on the role of HS in the development of graft inflammation and fibrosis.
Gradient Creation and Leukocyte Migration
Leukocyte recruitment is initiated by endothelial cell activation and chemokine presentation to leukocytes. However, the presence of chemokines alone is not sufficient to trigger leukocyte diapedesis. The spatial and temporal organisation of chemokines during inflammation is critical for leukocyte migration [5] . A higher chemokine concentration in the vessel wall and extravascular space generates a chemokine gradient along which leukocytes travel through the vessel wall and into the ECM [8••, 11, 12] . The binding of leukocytes to endothelial cells has been extensively studied. HS is important for the selectinmediated binding of neutrophils to the endothelium. P-and E-selectin expression on endothelial cells and L-selectin on neutrophils are important for neutrophil migration. Mice that lack an enzyme important for HS biosynthesis (NDST1) in endothelial cells and leukocytes demonstrate weak Lselectin-mediated binding and a reduced rolling velocity [13] .
The ECM is vital in generating and maintaining the chemokine gradient required for the cell migration, that occurs in graft rejection, embryonic development, formation of metastasis and infection. For example, in mouse skin, dendritic cells are guided toward lymphatic vessels by an endogenous gradient of CCL21. Dissociation of CCL21 from matrix HS using heparitinase diminishes the migration by disrupting the chemokine gradient [8••] . In another study, Massena et al. [12] analysed neutrophil migration in heparanase transgenic animals (hpa-tg mice). Overexpression of heparanase significantly reduced directional migration of neutrophils which was replaced by random crawling. These experiments highlight the importance of HS for leukocyte migration. (1) and adhere to the activated endothelium (2) . HS promotes adhesion to the vessel wall through chemokine gradient formation and presentation (2) and selectin interaction (not shown). Following basal lamina transmigration (3), the immune cells migrate via a chemokine gradient established by HS and reach the matrix surrounding the tubules (4). Secretion of pro-fibrotic factors by immune cells will activate fibroblasts (5) and lead to fibrosis and later tubular atrophy (6) . Top right image-HS structure and its multiple sulfation sites. HSPG heparan sulphate proteoglycans, Tyr/Ser-Thr tyrosine or serine-threonine kinase receptor, HS heparan sulphate. Figure was produced using Servier medical kit [10] GAGs Protect Chemokines from Enzymatic Degradation Proteolysis in the ECM is an active process responsible for matrix remodelling that also controls activity of non-matrix proteins. Chemokine degradation by metalloproteinases or peptidases would impact on the generation of an effective gradient and therefore leukocyte infiltration. The binding of chemokines to HS can protect them from proteolysis, increasing their half-life in the ECM and therefore supporting a higher chemokine concentration that is essential for leukocyte migration. For example, HS protects CXCL12 from degradation by the peptidase CD26/dipeptidyl peptidase IV [14] .
Regulation of Chemokines Activity by GAGs
HS is crucial for the activity of many chemokines and growth factors. HS does not only bind chemokines and growth factors but can also act as a scaffold for the assembly and presentation of ligands to their receptors [15] , increasing their activity at low concentrations [16] . Chemokines can be monomeric or form oligomers in solution. The monomeric form can bind its receptor and induce cell migration [17] . However, oligomerized chemokines can be more active than the monomeric form, and for some, it is an absolute requirement for their function in vivo [18] . Physiological activity of CCL5 relies on GAG binding-induced oligomerization [19] , and disrupting oligomerisation has been proposed as a novel therapeutic strategy to inhibit chemokine function.
These findings show that HS not only protects chemokines from degradation and helps create a gradient but also enhances ligand-receptor interactions of many molecules implicated in the development of IFTA. It triggers the activation of many signalling pathways by increasing the ability of chemokines and growth factors to bind their target receptors.
Interstitial Fibrosis
Once in the injured tissue, leukocytes such as macrophages, T cells and mast cells are important mediators of interstitial fibrosis. The degree of renal fibrosis is correlated with the extent of leukocyte infiltration. M2 macrophages, mast cells and T cells can release pro-fibrotic mediators (insulin-like growth factor-1, fibroblast growth factor 2 and transforming growth factor-β1) [20•] . Therefore, the presence of leukocytes in the renal interstitium promotes fibroblast activation and proliferation (see Fig. 1 ).
Interstitial fibroblasts can be derived from several sources including resident fibroblasts, bone marrow-derived fibrocytes and epithelial cells by the processes of epithelial to mesenchymal transition (EMT) [21] and endothelial to mesenchymal transition [22, 23] . Fibroblast proliferation and activation will lead to an increase in matrix biosynthesis which is also controlled by growth factors such as TGF-β and FGF2.
GAGs have a key role in controlling the fibrotic response as a consequence of the interaction between GAGs and growth factors. HS is implicated in the initiation of the signalling pathway of pro-fibrotic factors. Several studies that explored the interaction of TGF-β and HSPGs demonstrate that HSPG binds to the latent TGF-β-binding protein (LTBP) [24•] . TGF-β is initially synthesised as an inactive precursor which is cleaved to form the mature, active peptide. Two mature peptides are associated with two molecules of another protein, latency-associated peptide (LAP), to form a small latent complex. This is then covalently bound to the LTBP. This whole complex (the large latent complex) is then secreted from the cell where it can bind to the ECM, specifically HSPGs. Therefore, the ECM acts as a reservoir to TGFβ which can be activated in response to injury, and in the kidney, it contributes to progressive fibrosis [24•] . Furthermore, studies have demonstrated that HSPG expression on the cell surface is crucial for FGF2-induced renal fibroblast proliferation which is a prominent factor during interstitial fibrosis [25] .
Modification of GAGs During Matrix Remodelling
Biosynthesis, post-translational modifications and degradation of ECM proteins are key processes in tissue homeostasis and contribute to the development of irreversible fibrosis. As discussed above, the ECM is not simply a product of the fibrotic response, instead the biochemistry of the matrix can alter severity and type of injury.
HS proteoglycan expression can vary during embryonic development and ageing and during the development of disease [26] . In the kidney, the level of N-sulphated-HS is significantly increased during acute rejection [27] and 6-O-sulfation is increased in fibrotic renal disease [28] . Expression of the HSPG perlecan shows a significant increase in the glomeruli of rat renal allografts compared with isografts and nontransplanted kidneys [29] . These changes in the profile of tissue HSPGs may be the consequence of disease but, as discussed above, may then alter the outcome of injury. HSPGs could also have a protective role in transplantation. Increased syndecan-1 expression after transplantation is associated with low levels of proteinuria and lower serum creatinine. There is evidence that syndecan-1 is not simply a biomarker of renal function but has a causal role in protecting the allograft. Syndecan-1-deficient mice have worse renal function, tubular damage, and an increase in interstitial macrophages and myofibroblasts compared with wild-type mice following bilateral renal ischemia/reperfusion [30•] .
There is conflicting evidence that HS can either drive inflammation or have a protective role in transplantated kidneys. There are two explanations for those observations. Firstly, different matrix proteins can undergo post-translation modification by the addition of HS groups. Secondly, HS function will vary depending on the level and state of sulfation. Different enzymes regulate HS post-translational modification such as the addition of a sulphate group (sulfation) or an acetyl group (acetylation). Both modifications play a role in chemokine and growth factor binding and therefore in leukocyte recruitment and tissue fibrosis. Specific regions of HS selectively interact with chemokines and growth factors, and sulfation and acetylation at these sites will affect HS function. Sulfation generates a high negative charge on HS (see red groups Fig. 1 ) allowing positively charged molecules such as FGF-2 to bind with a low dissociation constant (Kd), and different sulfation patterns will modify the affinity of HS with FGF2 [31] . Heparin promotes the interaction between FGF and FGFR. Within the HS molecule, 2-O-sulfation is necessary for binding whereas 6-O-sulfation is required for FGF2-FGFR1 signalling [32] [33] [34] . A low Kd allows a very high affinity between these molecules which implies that a low concentration of FGF2 will be able to activate its signalling pathway. Therefore, cells having highly sulphated HS will be more sensitive to FGF2.
Enzymes Involved in HS Modification
After transplantation, there can be differential expression of HS-modifying enzymes, and this could modify HSchemokine and growth factor interactions and therefore cell infiltration and the fibrotic response. The expression of HSmodifying enzymes could impact multiple steps implicated in the development of IFTA (see Table 2 ).
Modifying HS impacts on early events in fibrosis. Recently, Massola V. et al. published two papers showing that, in human renal proximal tubular cell line (HK2), the silencing of heparanase, an enzyme that cleaves HSPG, inhibits EMT induced by FGF-2 and reduces TGF-β expression. The function of heparanase can vary depending on the scenario studied (see Table 2 ) [49] . As an example, mice overexpressing the enzyme show a drop in leukocyte recruitment; however, patients with ulcerative colitis, characterised by significant inflammatory cell infiltration, have an increase in heparanase expression [50] . Heparanase overexpression in these patients might be a response by the body to disrupt the chemokine gradient created by HS.
Taken together, these results show that the modulation of HS in the ECM and on cell membranes is crucial for the initiation of inflammation and fibrosis. However, if we look into inflammation and matrix remodelling processes, young patients with juvenile idiopathic arthritis have similar HS plasma and urinary concentrations compared to healthy controls [51] . It is probable that it is not only the presence of HS that determines function but also its sulfation pattern. HS sulfation modification will determine the ability of the transplant to recruit leukocytes, support inflammation and trigger fibrosis (see Table 2 ).
HS N-Sulfation and Acetylation Patterns
The N-sulfation pattern increases the negative charge present on HS and therefore increases its affinity for positively charged molecules such as chemokines and growth factors. The expression of N-sulphated HS is increased in acutely rejecting kidney. This observation can be explained by the effect that pro-inflammatory cytokines have on the expression of the two isoforms of N-deacetylase-sulphotransferase NDST [1, 2] increasing expression of both [52] . Also, it was found that following aortic transplantation in a mouse model, inflammatory cell invasion was significantly reduced in transplants from NDST-1-deficient donors [53] . Thus, it appears that the modulation of NDST expression by pro-inflammatory cytokines can modulate leukocyte infiltration, impact the capacity of HS to bind pro-fibrotic factors and, therefore, increase inflammation and fibrosis.
HS O-Sulfation Patterns
The level of O-sulfation of HS varies in the transplanted kidney. In human renal allograft, the use of specific antibodies targeting sulphate groups at N-, 6-O and 2-O positions show an increase in HS sulfation during chronic rejection [28] , a pattern that has been found important for FGF2 activity [54] . Additionally, N-and O-sulfation seems to modulate HSPG affinity to different growth factors [55] .
Furthermore, one isoform of HS3ST enzyme, the heparan sulphate D-glucosaminyl 3-O-sulfotransferase-3B1, when overexpressed in a pancreatic cell line promotes EMT [40] . The cells used in this study show, after transfection, a fibroblastic morphology, a decrease in E cadherin and b-catenin (epithelial markers), and an increase in mesenchymal markers. These results agree with the previous conclusion that the modulation of HS enzymes within an allograft can enhance the fibrotic response (see Table 2 ). However, it has been found that another isoform, HS3ST1, is overexpressed in tolerant, drug-free renal transplant recipients [41] . Little is known about the 3-O-sulphation of HS, and our current work is trying to resolve the mystery of the double-edged sword that is HS 3-O-sulfation.
Therapeutic Opportunities Mutant Chemokines
Knowledge of the interaction between HS and chemokines and growth factors [31, 56] allows design of compounds that do not bind HS [57] [58] [59] . These would interfere with gradient Improved renal function and reduced glomerular injuries (creatinine blood urea nitrogen; glomerular hyalinosis)
Acute inflammatory reaction (induced by IP thioglycollate); air pouch model Decrease in chemokine presentation, migration and neutrophil influx [13] Repetitive allergen exposure analyses of airway remodelling Less macrophage infiltration and peribronchial fibrosis compared to WT [36] NDST1−/− mice Generation of NDST1 null mice Non-viable, neonatal death due to lung defects Drop in leukocyte recruitment [12] Colon samples from ulcerative colitis; Hps tg mice Histology, mouse model of colitis Hps overexpression. Compared to WT, elevated hps in colonic epithelium have similar leukocyte infiltration during acute phase and increased mucosal infiltration during chronic phase [45] Hps−/− mice
LPS injection
Inhibition of neutrophil adhesion to pulmonary microvasculature [46] Hps-silenced tubular cells
Pro-fibrotic stimulation Reduced TGFβ synthesis, no change in EMT [47] Hps−/− effector T cells Injection of Hps−/− effector T cells in WT mice with lymph node or skin inflammation Hps not essential for lymphocyte extravasation through inflamed lymph nodes and inflamed skin vessels.
[48]
Hps −/− mice Zymosan-induced peritonitis Hps contributes to monocyte but not neutrophil entry to inflammation site [48] WT wild type, KO knock out; IP intraperitoneal; LPS lipopolysaccharides formation. For example, O'Boyle et al. analysed a non-HSbinding mutant (mt) CXCL12. In vivo, intravenous administration of a wild-type and mtCXCL12 mixture resulted in abolition of the chemotactic potential of the wild-type chemokine to recruit leukocytes in a murine air pouch model. In vitro, the ability of wtCXCL12 to induce peripheral blood mononuclear cells to migrate across an endothelial monolayer was abolished when mtCXCL12 was mixed with wild-type CXCL12 [58] . Following isograft skin transplantation, injection of a non-GAG-binding CCL7 inhibits leukocyte infiltration [60] . In rat allograft, skin transplantation, administration of synthetic octapeptides derived from the murine-binding sequence of interferon gamma blocks the binding of the whole protein and some chemokines to HS and delays rejection [61, 62] . In another approach, mutant chemokines with an increased ability for binding GAG [63] and sometimes with also a decreased ability for receptor activation [64•] are also being studied. Recently, one of these mutants for CXCL8 named PA401 that displays increased binding to HS but no binding to the receptor and therefore displaces the WT CXCL8 from ECM was shown in vitro to decrease CXCL8 levels in airway fluid from patients suffering from cystic fibrosis and to reduce neutrophil chemotaxis [65] .
Chemokines acting as chemokine receptor antagonists are also under study. As an example, Met-CCL5 is a methionylated form of the chemokine CCL5 and is a ligand for CCR1, CCR3, CCR5, CCR9 and ACKR1 in humans. In a renal transplant model, rats treated with Met-CCL5 injection have a significant decrease in tubular damage, leukocyte and macrophages infiltration and vascular injury [66, 67] .
Viral Chemokines
The study of viruses led to the discovery of viral chemokines that have the ability to modify the chemokine network. Viral chemokine-binding proteins such as myxoma virus protein M-T7 are of great interest as they can interfere with the chemokine-GAG binding domains, although the molecular mechanism underlying MT7 action is still under investigation [68] . Several studies using M-T7 show that interfering with the GAG-binding domain of chemokines is an effective way of diminishing vascular inflammation and cell invasion. In a murine model of renal transplantation, M-T7 treatment increases allograft survival [53] and can prevent chronic rejection [69] . Furthermore, following vascular balloon injury, intimal hyperplasia was inhibited by MT7 protein infusion [70] . It was hypothesised that the effect of M-T7 activity on vascular inflammation is due to its interaction with sulphated HS located on endothelial cells. In support of this in an aortic allograft model, MT7 only affects intimal inflammation and thickness in wild-type mice but not in mice deficient in NDST1. Similarly in a mouse peritoneal ascites model, M-T7 treatment decreased cell invasion in WT but not in NDST1−/− mouse [53] . This highlights again the major role of sulphated HS-chemokine interactions in inflammation. Thus, the GAG binding of chemokines appears to be the potential target for future therapies for allograft inflammation and IFTA.
Evasins
The discovery of inhibitory effects of tick saliva on proinflammatory cytokines led to the detection of small proteins (60-79 amino acids) named Evasins [71] that can bind chemokines and inhibit cell recruitment in vitro and have anti-inflammatory activities in murine models [72] . They can inspire synthetic peptides for chemokine neutralising and are now of great interest to define the binding sequence [73] .
HS Mimetics
Small HS mimetics can be developed to better understand HS sulphation patterns required for pro- [74] and antiinflammatory activities considering the impact on heparanase action [75] and chemokine/growth factor binding [76] . Depending on their composition and length, these small mimetics have been found to be effective in inhibiting the interaction between fibroblast growth factor-1, FGF2 and vascular endothelial growth factor with immobilised heparin [76] . Furthermore, the use of a trisulphated HS mimetic can inhibit CCL5 chemotactic action in vitro [77] .
Biomarkers
Non-invasive techniques to diagnose rejection in allograft kidneys require representative biomarkers of the graft's immune status. Biomarkers that could serve as predictive tools for rejection might help to stratify patients for individualised treatment and allow early intervention. Increasing understanding and screening of specific mRNA in renal transplant recipients have provided various candidate biomarkers [78] . HS enzymes have been proposed as biomarkers of tolerance [41] and chemokines for acute rejection [79] . A cleavage product of the proteoglycan agrin named CAF (C-terminal agrin fragment) has been found to be significantly correlated with delayed graft function at 1-3 days post-renal transplantation. Furthermore, the serum concentration of CAF drops faster than creatinine which makes it a potential biomarker for renal recovery after transplantation [80••] . An elevated serum level of LG3, a C-terminal fragment of perlecan, is associated with graft loss in patients with acute vascular rejection [81] . In kidney transplant recipients, the glomerular filtration rate has been found to be inversely associated with elevated concentrations of heparanase in the urine [82] .
Conclusion
Heparan sulphate is potentially a major player in the events leading to inflammation and fibrosis. However, it could play both pro-inflammatory and anti-inflammatory roles. As one enzyme involved in HS sulfation is overexpressed in tolerant patients (HS3ST1) [41] , it might be of interest to look at other enzymes/isoforms present in different patient samples. This may lead to the development of new biomarkers that could differentiate tolerant patient from a patient with chronic graft rejection.
